 Immunologic Factors
"Immunologic Factors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Biologically active substances whose activities affect or play a role in the functioning of the immune system.
| Descriptor ID |
D007155
|
| MeSH Number(s) |
D27.505.696.477
|
| Concept/Terms |
Immunologic Factors- Immunologic Factors
- Immune Factors
- Factors, Immune
- Immunological Factors
- Factors, Immunological
- Factors, Immunologic
|
Below are MeSH descriptors whose meaning is more general than "Immunologic Factors".
Below are MeSH descriptors whose meaning is more specific than "Immunologic Factors".
This graph shows the total number of publications written about "Immunologic Factors" by people in this website by year, and whether "Immunologic Factors" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 1 | 3 | | 2000 | 1 | 0 | 1 | | 2003 | 1 | 1 | 2 | | 2005 | 2 | 1 | 3 | | 2006 | 4 | 0 | 4 | | 2007 | 2 | 0 | 2 | | 2008 | 3 | 1 | 4 | | 2009 | 9 | 4 | 13 | | 2010 | 3 | 2 | 5 | | 2011 | 5 | 4 | 9 | | 2012 | 5 | 1 | 6 | | 2013 | 8 | 1 | 9 | | 2014 | 5 | 1 | 6 | | 2015 | 6 | 1 | 7 | | 2016 | 5 | 6 | 11 | | 2017 | 5 | 3 | 8 | | 2018 | 9 | 0 | 9 | | 2019 | 8 | 2 | 10 | | 2020 | 9 | 8 | 17 | | 2021 | 3 | 4 | 7 | | 2022 | 2 | 9 | 11 | | 2023 | 0 | 2 | 2 | | 2024 | 1 | 5 | 6 | | 2025 | 5 | 0 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Immunologic Factors" by people in Profiles.
-
Bennett JL, Fujihara K, Saiz A, Traboulsee AL, Greenberg BM, Weinshenker BG, Patti F, Kleiter I, Palace J, De Seze J, Evans R, Blondeau K, Klingelschmitt G, Vodopivec I, Rahim M, Yamamura T. Long-Term Efficacy and Safety of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder From the SAkuraMoon Open-Label Extension Study. Neurol Neuroimmunol Neuroinflamm. 2025 Sep; 12(5):e200450.
-
Greenberg BM, Fujihara K, Weinshenker B, Patti F, Kleiter I, Bennett JL, Palace J, Blondeau K, Burdeska A, Ngwa I, Klingelschmitt G, Triyatni M, Yamamura T. Analysis of infection rates in neuromyelitis optica spectrum disorder: Comparing satralizumab treatment in SAkuraMoon, post-marketing, and US-based health claims data. Mult Scler Relat Disord. 2025 Jul; 99:106444.
-
Kwak-Kim J, Maier CC, Villano CM, Bowman CJ, Brennan FR, Stanislaus D, Hillegas A, Krayer J, Prell RA, Papenfuss TL, Cauvin A, Gamse J, Dahlman A, Enright B, Leshin L, Rao GK, Helms W, Fuller CL, Yang X, Chen C, Mitchell-Ryan S. Assessing the impact and risk of immunomodulatory compounds on pregnancy. J Reprod Immunol. 2025 Jun; 169:104453.
-
Corboy JR, Fox RJ, Cutter G, Engebretson E, Miller A, Morgan C, Gustafson T, Goodman AD, Kannan M, Sriram S, Xia Z, Lynch S, Bowen J, Kister I. DISCOntinuation of disease-modifying therapies in MS: The DISCOMS extension trial. Mult Scler. 2025 Feb; 31(2):159-173.
-
Mar S, Valeriani M, Steinborn B, Schreiner T, Waubant E, Filippi M, Kotulska K, Mazurkiewicz-Beldzinska M, El Azzouzi B, Lin CJ, Shen YA, Kletzl H, Evershed J, Hogea A, Manlius C, Bonati U, Banwell B. Ocrelizumab dose selection for treatment of pediatric relapsing-remitting multiple sclerosis: results of the OPERETTA I study. J Neurol. 2025 Jan 15; 272(2):137.
-
Virupakshaiah A, Schoeps VA, Race J, Waltz M, Sharayah S, Nasr Z, Moseley CE, Zamvil SS, Gaudioso C, Schuette A, Casper TC, Rose J, Flanagan EP, Rodriguez M, Tillema JM, Chitnis T, Gorman MP, Graves JS, Benson LA, Rensel M, Abrams A, Krupp L, Lotze TE, Aaen G, Wheeler Y, Schreiner T, Waldman A, Chong J, Mar S, Waubant E. Predictors of a relapsing course in myelin oligodendrocyte glycoprotein antibody-associated disease. J Neurol Neurosurg Psychiatry. 2024 Dec 16; 96(1):68-75.
-
Abbott KS, Palestine AG, Hauswirth SG, Gregory DG, Patnaik JL, Reddy AK. Treatment of Ocular Surface Disease in Ocular Cicatricial Pemphigoid. Ocul Immunol Inflamm. 2024 Dec; 32(10):2479-2485.
-
Gross RH, Corboy J. De-escalation and Discontinuation of Disease-Modifying Therapies in Multiple Sclerosis. Curr Neurol Neurosci Rep. 2024 Sep; 24(9):341-353.
-
Bove R, Applebee A, Bawden K, Fine C, Shah A, Avila RL, Belviso N, Branco F, Fong K, Lewin JB, Liu J, England SM, Vignos M. Patterns of disease-modifying therapy utilization before, during, and after pregnancy and postpartum relapses in women with multiple sclerosis. Mult Scler Relat Disord. 2024 Aug; 88:105738.
-
Nasr Z, Casper TC, Waltz M, Virupakshaiah A, Lotze T, Shukla N, Chitnis T, Gorman M, Benson LA, Rodriguez M, Tillema JM, Krupp L, Schreiner T, Mar S, Rensel M, Rose J, Liu C, Guye S, Manlius C, Waubant E. Clinical and magnetic resonance imaging outcomes in pediatric-onset MS patients on fingolimod and ocrelizumab. Mult Scler Relat Disord. 2024 Jul; 87:105647.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|